(a) hepatic uptake determined by direct tissue measurement could be accurately estimated from the plasma disappearance data; (b) saturation of hepatic uptake with increasing dose was readily demonstrated for each of these three organic anions, and in each instance a plot of V versus dose took the form of a rectangular hyperbola analyzable in terms of Michaelis-Menten kinetics; (c) for BR, the saturable uptake process showed a V.a. more than 100 times the normal net transfer rate from plasma to bile; (d) hepatic uptake of BR, BSP, and ICG showed relatively selective, mutually competitive inhibition; glycocholic acid did not inhibit hepatic uptake of any of these substances; and (e) "countertransport" could be demonstrated for each of the three test substances. These data are compatible with the existence of a carrier-mediated transport process for hepatic uptake of each of these three organic anions and clarify the relationship of hepatic BR uptake to its overall transport from plasma to bile.
INTRODUCTION
Nonvolatile metabolic waste products such as bilirubin (BR)1, as well as many exogenously administered drugs Part of this work was published previously in abstract form. Gastroenterology. 67 :A-50/827; 1974.
Received for publication 1 April 1975 and in revised form 8 July 1975. 'Abbreviations used in this paper: BR, bilirubin; ICG, indocyanine green; BSP,sulfobromophthalein; SD, Sprague or dyes, circulate in plasma bound to albumin and are cleared from the circulation almost exclusively by the liver. For many of these substances, this transfer from sinusoidal blood to bile involves at least three steps: hepatic uptake, conjugation, and biliary excretion. Although it is possible to measure overall hepatic clearance of substances such as BR (1), it is not generally possible to quantitate each of these individual processes.
While the conjugating enzyme, maximal excretory capacity, or both have been identified for some of these substances, the process of hepatic uptake and its relation to overall hepatic transport remains poorly characterized. This paper describes studies of hepatic BR, indocyanine green (ICG), and sulfobromophthalein (BSP) uptake performed in approximately 350 intact, anesthetized Sprague-Dawley (SD) and 15 Gunn rats. Evidence is presented that suggests that hepatic uptake of each of these organic anions involves a process of facilitated transport that can be quantitated in terms of MichaelisMenten kinetics (2) , and that these anions show relatively specific, mutually competitive inhibition. In addition, the effect on hepatic uptake of physiologic variables such as fasting and the administration of enzyme inducing drugs has been studied. METHODS Animials. Male SD (Taconic Farms, Inc., Germantown, N. Y.) or Gunn rats (Animal Resources Branch, National Institutes of Health) weighing from 280 to 450 g were used in all studies. Before the study, each rat was anesthetized with a 50 mg/kg intraperitoneal dose of pentobarbital (Veterinary Laboratories, Inc., Lenexa, Kans.) and the right jugular vein and carotid artery were cannulated with PE-10 and PE-50 (Clay Adams, Div. of Becton, continuously recorded with a deep rectal probe (TeleThermometer, Yellow Springs Instrument Co., Yellow Springs, Ohio) and maintained at .50C with an infrared lamp. Unless specifically stated otherwise, rats were not fasted and only one study was performed in each animal. Preparation of radiolabeled BR and BSP. Unconjugated [3H] BR was prepared in bile fistula dogs as previously described (3) . When solutions of radiolabeled BR mixed with unlabeled BR were diazotized with para-iodoaniline according to the method of Van Roy, et al (4) , an average of 96.2% of the isotope was extracted into the butyl acetate (azopigment-containing) layer. Thin layer chromatographs of butyl acetate extracts (5) Substances used for injection. BR solutions were prepared by dissolving crystalline BR (ICN Nutritional Biochemicals Div., International Chemical & Nuclear Corp., Cleveland, Ohio) in a saline-sodium carbonate solution (5.2 g each of NaCl and Na2COS/liter) and then adjusting to pH 8 with 5 N HCl. The actual BR concentration in this solution was then measured in duplicate before its use for bolus injections or infusion. BR photodegradation products were formed in vitro by a method similar to that previously described (7) . A concentrated (240 mg/ 100 ml) solution of BR in rat plasma was circulated around Westinghouse Special Blue bulbs (F20T12/BB) (Westinghouse Electric Corp., Pittsburgh, Pa.) for 16 h.
Although no attempt was made to characterize these products structurally, they appeared almost exclusively in the upper layer of a Weber-Schalm (6) partition. Results from similar experiments done in this laboratory (7) also suggest that BR photodegradation products formed in this manner are about 50% bound to albumin-conjugated agarose beads (8) (9) . BR concentration in prepared solutions and in rat plasma was determined by the method of Weber and Schalm (6) or a micro-modification of this same technique. BSP concentration was measured by the method of Gaebler (10) . ICG concentration in rat plasma was determined by comparing the optical density at 805 nm with standard curves of ICG dissolved in rat plasma. In studies with ICG doses of 1 mg/kg or more, plasma samples were diluted in 1% human serum albumin. In these studies standard curves were constructed with the same dilution of rat plasma in human serum albumin and varying ICG concentrations.
Hepatic ICG content was measured by a method analogous to that of Paumgartner et al. (11) . 1-3 g of liver tissue was homogenized in saline and the volume adjusted to 25 ml with saline. Total volume of the homogenate was increased to 50 ml by addition of acetone, and the mixture was shaken vigorously and centrifuged at 3,000 rpm for 15 min in the cold. The optical density at 805 nm of the supernate was read against a blank consisting of a similar extract of normal liver tissue and then compared with standard curves of ICG dissolved in a 1: 1 (vol: vol) mixture of saline and acetone. [BR] (itmol/ml) *PVDBR (ml/kg) (3) by itself yields the total micromoles per kilogram of BR circulating in the plasma at the time of ['H]BR injection. Since this is equivalent to the injected BR dose (D) in micromoles per kilogram used in bolus injection studies, it is hereafter referred to as the "equivalent BR dose". Implicit in this analysis is the assumption that BR in the extravascular (nonhepatic) compartment exchanges slowly with the plasma pool and need not be considered in these calculations. This is supported by the nearly complete hepatic recovery of injected BR (vide infra) as well as BR kinetic studies in man (1) and rats (12) .
Data from the bolus injection studies was further analyzed in terms of Michaelis-Menten (2) If the percent inhibition produced by a fixed dose of inhibitor decreased as the dose of the organic anion (whose plasma disappearance rate was being measured) increased, and the value for V..a. determined by the Lineweaver-Burk plot in the presence of inhibitor was not significantly different from the value in its absence, then the data were felt to be compatible with competitive-type inhibition.
It would have also been desirable to establish that noncompetitive inhibition was not present. This would require demonstration of a significant increase in the "apparent Ki" for a particular organic anion in the presence of its inhibitor, and could best be achieved by injecting large doses of inhibitor to increase the slope maximally and decrease the absolute value of the x intercept of the Lineweaver-Burk plot without changing the y intercept. In practice, it was often impossible to use the large doses of inhibitor required without exceeding the usual volume of injection or killing the animal.
When significant inhibition wvas present, a value for K1
(the dose of inhibitor in micromoles per kilogram required to decrease the plasma disappearance rate of an infinitely small dose of organic anion by 50%) was calculated from the increment in slope in the Lineweaver-flurk plot produced by the inhibitor with the following equation (2) ( 5) in which I is the dose of inhibitor in micromoles per kilogram.
Hepatic [ were used in the calculation of plasma disappearance rates.
The plasma disappearance curves of BR, BSP, and ICG, when studied over a longer time, are best represented by a sum of two or more exponential functions of the form q(t) = Nle-alt + N2e.-a2t... Nne-ant where q(t) equals the fraction of injected isotope in plasma at time t, and Ni + N2 . . . N. equals 1. The presence of n exponentials in the plasma disappearance curve of a substance implies that there are n-1 addi8Unpublished observations. tional pools in equilibrium with the plasma (15, 16) . This system of plasma plus n-1 additional pools, including the intrahepatic pool, can be described in terms of a compartmental model, and such models have been formulated and validated for BR (1), BSP (17, 18) , and ICG (19) . For each of these models the fractional hepatic uptake rate, X2,1, is a function of all the N's and a's of the plasma disappearance curve, q(t). However, empirically, the value of X2,1 is closely approximated by k, the initial plasma fractional disappearance rate. This has been shown to be true in normal men for both radiobilirubin (k = 0.023+[SD] 0.007 min'; X2,1 = 0.024+0.007 min') and BSP (k = 0.124+0.019 min'; X21 = 0.139±0.024 min') (1, 20) .'
To assess the potential magnitude of the error introduced by approximating X2,1 with k in these experiments, detailed studies of radiobilirubin kinetics were done over a period of 3 h in eight male SD rats given an average dose of 0.154 ,mol/kg of [ The results of the studies in which animals were given an infusion of unlabeled BR followed by a tracer dose of ['H]BR are presented both graphically ( Fig. 2A) and in tabular form (Table II) . By varying the infusion rate, a wide variety of BR concentrations (0.6 -53.4 mg/100 ml), corresponding to a wide range of equivalent BR doses (0.32 -29.8 umol/kg) was produced. If saturation of hepatic BR uptake had occurred Fig. 2B . Lineweaver-Burk transformation of these data (Table IV, Fig. 3) Fig. 3 ) that both ICG and BSP behave as competitive inhibitors of hepatic BR uptake. That is, they increased the slope of the Lineweaver-Burk plot without significantly altering Vm... Finally, it is apparent that ICG (Ki = 206±46) is a much weaker inhibitor of hepatic BR uptake than is BSP (Kr = 27±2).
The results of similar studies with ICG ( (Table IV) for Vm.. (1.67+ 0.23) calculated from these studies was somewhat larger than in controls and that for Km (3.58±0.56) was somewhat lower. However, these differences were not statistically significant (P> 0.3 for both).
Effect of fasting on organic anion uptake. The plasma disappearance rate of both a low dose and high dose of BR, ICG, and BSP was measured in a total of 44 rats allowed access only to water for 72 h before the study. This period of fasting caused an average 9.7% decrease in body weight, and a 28.8% (P < 0.001) decrease in liver weight expressed as a percent of body weight. As shown in Table III , fasting did not significantly affect the plasma BR disappearance rate of either dose, and values for Vrma.; (1.67±1.25) and Km (4.73± 3.84) (Table IV) are similar to controls. In contrast, the plasma ICC fractional disappearance rate (Table V) was decreased by 19.5%o (P < 0.02) at the low dose (0.5 mg/kg; 0.645 ytmol/kg) and 37.2%
(P <0.02) at the higher dose (5.0 mg/kg; 6.45 ismol/ kg). Plasma BSP disappearance rates were similarly affected at both low (0.064 mg/kg; 0.077 ytmol/kg) and higher (10.3 mg/kg; 12.3 ztmol/kg) doses, and again, the disappearance rate of the higher dose was decreased to a greater extent (35.4%; P < 0.01) than the low dose (19.3%; P < 0.01). With a Lineweaver-Burk plot, it was possible to estimate the corresponding changes in Vmaw and Km (Table IV) . Unlike BR, fasting caused an appreciable decrease in both parameters for (24) (25) (26) .
DISCUSS ION
These studies demonstrate that the hepatic uptake of BR, BSP, and ICG each shows three properties considered strong evidence for the presence of carriermediated transport (24) (25) (26) . These are: (a) saturation with increasing dose; (b) relatively selective, mutually competitive inhibition; and (c) countertransport.
These studies complement work done by previous investigators who have shown (a) that the hepatic uptake of ICG (11, 27, 28) , BSP (24, 28, 29) , and BR (30) (32) . If the simplifying assumption is made that the entire 7 mg is transported from plasma into the liver, then the normal net transfer rate of BR from plasma into the liver in SD rats is approximately 10 nmol/kg/min. This is less than 1% of 1.44 /Amol/kg/min, the maximal uptake capacity. It would thus seem unlikely that uptake is, under normal circumstances, the rate-limiting step in the overall transport of studies in which rats were given a bolus of BR without prior infusion. This is especially surprising since the calculated initial BR concentration at which half-maximal hepatic uptake occurred (6.2 mg/100 ml) in the bolus injection studies was much less than the highest concentration produced by infusion (53.4 mg/100 ml). A potential explanation for these findings may lie in the differing experimental conditions. Whereas loading studies acutely increase plasma BR concentration without immediately affecting intrahepatic BR concentration, prolonged BR infusion increases both (33) . Thus, large doses of BR appear to enter the liver more rapidly when intrahepatic BR concentration is increased by prior BR infusion.
A precedent for this type of finding exists in previous studies of membrane transport in other systems. The observation has been made that glucose is transported out of human erythrocytes more rapidly in the presence of extracellular glucose than in its absence (34, 35) .
Other investigators have demonstrated that preloading Ehrlich ascites tumor cells with glycine increases the initial transport rate of labeled glycine into the cell (36) . Depending upon the particular experimental model in which it was observed, this type of phenomenon has been called "accelerative exchange diffusion" (26) or "preloading effect" (37) and has been explained with the model of carrier-mediated transport. This model assumes the presence of carriers within the cell membrane. These carriers bind reversibly with substrate at either surface of the membrane to form a complex, and can diffuse (or "move" in some kinetically equivalent fashion) either as free carrier or as complex from one side to the other. In this way, substrate, which by itself diffuses very slowly if at all across the membrane, is transported into or out of the cell.
In these studies, the unidirectional flux of BR into the hepatocyte is measured by the rate of disappearance of labeled BR from the plasma. This unidirectional flux depends upon the rate at which carrier-BR complex diffuses into the cell, as well as the rate of return of carrier molecules to the external surface. If the diffusion rate of free carrier is much slower than that of complex (26) , the return of carrier molecules to the external surface would be accelerated by increasing intracellular BR concentration. Thus, infusion studies, which increase intra-and extracellular BR concentration, might be less likely to demonstrate saturation than bolus injection studies.
Other investigators who have emphasized the fact that the "preloading" effect seems to be a property of concentrative transport systems only, have developed an alternative hypothesis (37, 38) . This model does not require the assumption that the diffusion rate of free carrier differs from that of complex. Instead, the carrier is postulated to be present in the membrane in two mobile, interconvertible forms that differ in their substrate affinity. Kinetic analysis of this model (37) has shown that it agrees well with published data on the transport of glycine into Ehrlich ascites tumor cells and explains the preloading effect as well as other properties of concentrative membrane transport systems.
Finally, the results of these studies allow speculation about the potential role of cytoplasmic proteins such as "Y" and "Z" (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) very weakly with BR for hepatic uptake. Also, the generally held model of facilitated transport described above is that of a carrier-mediated process in which movement of the carrier molecules is restricted to within the cell membrane. All of these observations would suggest that cytoplasmic proteins such as Y and Z do not play a primary role in the membrane transport process responsible for the intial uptake of organic anions. Rather, it is probable that they secondarily affect net transport by their function as intracellular "storage" proteins.
